Company: SMNR
Filing Date: 2025-09-26
Form Type: 8-K
Source: 0001193125-25-220455
Chunk: 10

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-09-26
Form: 8-K
Item: Item 8.01
Chunk 10
---
Item 8.01.      Other Events.  

By operation of Rule12g-3(a)under the Exchange Act, the Company is the successor issuer to Denali and has succeeded to the attributes of Denali as the registrant, including Denali’s SEC file number(001-41351)and CIK Code (0001913577). The Company’s common stock and public warrants are deemed to be registered under Section 12(b) of the Exchange Act, and the Company will hereafter file reports and other information with the SEC using Denali’s SEC file number(001-41351).

The Company’s common stock and public warrants are traded on the OTC Markets under the symbols “ SMNR” and “ SMNRW,” respectively, and the CUSIP numbers relating to the Company’s common stock and public warrants are 81686G 105 and 81686G 113, respectively.

Holders of Denali’s shares who have filed reports under the Exchange Act with respect to those shares should indicate in their next filing, or any amendment to a prior filing, filed on or after the Closing Date that the Company is the successor to Denali.

  Item 9.01.      Financial Statements and Exhibits.  

(a) Financial statements of businesses acquired.

The unaudited condensed consolidated financial statements of Denali as of and for the three and six months ended June 30, 2025 and 2024, and the related notes thereto beginning on page 1 of Denali’s Quarterly Report on Form10-Q, filed with the SEC on August 15, 2025 (the “ Form10-Q”), are incorporated herein by reference. These unaudited condensed consolidated financial statements should be read in conjunction with the historical audited financial statements of Denali for the years ended December 31, 2024 and 2023 and the related notes included in the Proxy Statement/Prospectus beginning on pageF-2thereof, which are incorporated herein by reference.

The unaudited standalone financial statements of Legacy Semnur as of and for the three and six months ended June 30, 2025 and 2024 are set forth in Exhibit 99.3 hereto and are incorporated herein by reference. These unaudited standalone financial statements should be read in conjunction with the historical audited financial statements of Legacy Semnur for the years ended December 31, 2024 and 2023 and the related notes included in the Proxy Statement/Prospectus beginning